Blog Posts - Grazoprevir/elbasvir (mk-5172/mk-8742



ILC2016 Head-to-head study: once daily oral combination of elbasvir and grazoprevir versus sofosbuvir and pegylated interferon alpha 2b + ribavirin

 Newly approved all-oral Hepatitis C combination drug found more effective in a head-to-head comparison April 14, 2016 Press Releases Head-to-head study: once daily oral combination of... Monday HCV News Ticker- Hepatitis C: Coffee, Medicare...
by HCV New Drug Research on Apr 14, 2016

Merck to Present New Data on HCV Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015

Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations New... Monday HCV News Ticker- Hepatitis C: Coffee, Me...
by HCV New Drug Research on Oct 20, 2015

FDA Acceptance of NDA for Merck's Grazoprevir/Elbasvir Treatment of Hepatitis C Genotypes 1, 4 and 6 Infection

Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6... Monday HCV News Ticker- Hepatitis C: Coffee, Medic...
by HCV New Drug Research on Jul 28, 2015

Single Pill Combination Therapy For Some Hepatitis C Subtypes

Single Pill Combination Therapy For Some Hepatitis C Subtypes Posted on April 26, 2015 Source- MedicalResearch .com  Interview with: Stefan Zeuzem, MD Professor of Medicine Chief Department of... Monday HCV News Ticker- Hepatitis C: Coffee, Med...
by HCV New Drug Research on Apr 26, 2015

Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

Data Sets Include Treatment-Naïve, Treatment-Experienced and HIV Co-Infected Patients with Chronic Hepatitis C Virus Genotypes 1, 4 or 6 Infection Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA...
by Hepatitis C Research and News on Apr 24, 2015

Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease

C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1 Thursday, April 2...
by Hepatitis C Research and News on Apr 23, 2015

Merck & Co. to submit grazoprevir, elbasvir hepatitis C combination to FDA in 2015

(Ref: Merck & Co., The Lancet, StreetInsider, NASDAQ) November 11th, 2014 By: Joe Barber Merck & Co. said Tuesday that it plans to submit a marketing application for its investigational combination regimen of grazoprevir and elbasvir t...
by Hepatitis C Research and News on Nov 11, 2014

Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients

Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting® and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 20...
by Hepatitis C Research and News on Nov 11, 2014

Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®

Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Merck’s Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 Sunday, November 9, 2014 6:53 pm EST BOSTON--(BUSINESS WIRE...


Trending Topics

Close